Private equity firm Antin Infrastructure Partners (Euronext Paris:ANTIN) announced on Thursday that it has agreed to acquire Emsere from Dutch family investment platform Gryphion.
Emsere, headquartered in Leiden in the Netherlands, is a medical equipment rental specialist providing clinical trial equipment and logistics solutions to pharmaceutical companies and contract research organisations (CROs) globally.
Founded in 1996, Emsere manages over 13,000 pieces of equipment and delivers to more than 100 countries, serving six of the top 10 global pharmaceutical companies and seven of the top 10 CROs. Its portfolio includes centrifuges, imaging devices, cardiovascular and respiratory monitors, and cardio-pulmonary exercise testing equipment.
The company operates in the growing clinical trial equipment rental market, addressing demand for outsourced, complex, and regulatory-compliant solutions delivered at scale. Emsere's services allow clients to focus on scientific and clinical execution while avoiding capital expenditure and logistical coordination.
Antin's investment marks the eighth for its EUR2.2bn Mid Cap Fund I and continues its strategy of scaling health and medical infrastructure companies in Europe and North America. Emsere's CEO Patrice Gerard and senior management will co-invest alongside Antin.
The transaction is expected to close in the first quarter of 2026.
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
Datroway approved in EU for first-line metastatic triple-negative breast cancer
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
BeOne Medicines expands US manufacturing with USD300m investment
GSK's Jideytro (zidesamtinib) gains US approval for previously treated ROS1-positive NSCLC
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Insilico initiates Rentosertib Phase III clinical trial for idiopathic pulmonary fibrosis
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer